Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shanzhi Gu

Showing results (51-60 of 79) with videos related to

Pageof 8
Sort By:
Radiology|December 13, 2017
<sup>18</sup>F-FDG PET Biomarkers Help Detect Early Metabolic Response to Irreversible Electroporation and Predict Therapeutic Outcomes in a Rat Liver Tumor ModelXifu Wang, Zhanliang Su, Tianchu Lyu, et al.
Journal for Immunotherapy of Cancer|February 22, 2024
First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trialShengxiang Ren, Xicheng Wang, Bao-Hui Han, et al.
International Journal of Cancer|April 3, 2016
Early sorafenib-related adverse events predict therapy response of TACE plus sorafenib: A multicenter clinical study of 606 HCC patientsYan Zhao, Hailiang Li, Wei Bai, et al.
Cancer Immunology, Immunotherapy : CII|May 10, 2024
Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket studyShengxiang Ren, Anwen Xiong, Jia Yu, et al.
Advances in Therapy|May 23, 2026
First-Line Pembrolizumab Plus Chemotherapy for Advanced Biliary Tract Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-966 StudyZhenggang Ren, Tingbo Liang, Shanzhi Gu, et al.
Journal of Hepatology|March 28, 2025
Health-related quality of life in participants with advanced biliary tract cancer from the randomized phase III KEYNOTE-966 studyChanghoon Yoo, Makoto Ueno, Heinz-Josef Klümpen, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|July 26, 2017
[Expert Consensus for Thermal Ablation of Primary and Metastatic Lung Tumors 
(2017 Edition)]Xin Ye, Weijun Fan, Hui Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2025
Porustobart (HBM4003) plus toripalimab as second-line therapy in patients with advanced hepatocellular carcinoma: a multicenter, open-label, phase I studyNingning Zhang, Tian Liu, Ming Luo, et al.
Scientific Reports|April 28, 2024
Surgical treatment improves overall survival of hepatocellular carcinoma with extrahepatic metastases after conversion therapy: a multicenter retrospective studyXiaoshi Zhang, Xiaodong Zhu, Jianhong Zhong, et al.
Journal of Cancer Research and Therapeutics|July 5, 2018
Expert consensus workshop report: Guidelines for thermal ablation of primary and metastatic lung tumors (2018 edition)Xin Ye, Weijun Fan, Hui Wang, et al.
Pageof 8

Showing results (51-60 of 79) with videos related to

Sort By:
Pageof 8
Radiology|December 13, 2017
<sup>18</sup>F-FDG PET Biomarkers Help Detect Early Metabolic Response to Irreversible Electroporation and Predict Therapeutic Outcomes in a Rat Liver Tumor ModelXifu Wang, Zhanliang Su, Tianchu Lyu, et al.
Journal for Immunotherapy of Cancer|February 22, 2024
First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trialShengxiang Ren, Xicheng Wang, Bao-Hui Han, et al.
International Journal of Cancer|April 3, 2016
Early sorafenib-related adverse events predict therapy response of TACE plus sorafenib: A multicenter clinical study of 606 HCC patientsYan Zhao, Hailiang Li, Wei Bai, et al.
Cancer Immunology, Immunotherapy : CII|May 10, 2024
Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket studyShengxiang Ren, Anwen Xiong, Jia Yu, et al.
Advances in Therapy|May 23, 2026
First-Line Pembrolizumab Plus Chemotherapy for Advanced Biliary Tract Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-966 StudyZhenggang Ren, Tingbo Liang, Shanzhi Gu, et al.
Journal of Hepatology|March 28, 2025
Health-related quality of life in participants with advanced biliary tract cancer from the randomized phase III KEYNOTE-966 studyChanghoon Yoo, Makoto Ueno, Heinz-Josef Klümpen, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|July 26, 2017
[Expert Consensus for Thermal Ablation of Primary and Metastatic Lung Tumors 
(2017 Edition)]Xin Ye, Weijun Fan, Hui Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2025
Porustobart (HBM4003) plus toripalimab as second-line therapy in patients with advanced hepatocellular carcinoma: a multicenter, open-label, phase I studyNingning Zhang, Tian Liu, Ming Luo, et al.
Scientific Reports|April 28, 2024
Surgical treatment improves overall survival of hepatocellular carcinoma with extrahepatic metastases after conversion therapy: a multicenter retrospective studyXiaoshi Zhang, Xiaodong Zhu, Jianhong Zhong, et al.
Journal of Cancer Research and Therapeutics|July 5, 2018
Expert consensus workshop report: Guidelines for thermal ablation of primary and metastatic lung tumors (2018 edition)Xin Ye, Weijun Fan, Hui Wang, et al.
Pageof 8